Journal of Diagnostics Concepts & Practice >
Genotype and clinical phenotype in congenital generalized lipodystrophy type 1: analysis and literature review
Received date: 2022-01-19
Online published: 2023-01-29
Objective: To explore the genotype and clinical phenotype of congenital generalized lipodystrophy type 1(CGL1), and to improve awareness of the disease. Methods: A patient with severe acanthosis nigricans was diagnosed as having CGL1, and the clinical information and results of laboratory and gene tests were analyzed. Five Chinese cases with CGL1 in the database were literaturally reviewed. Results: The patient was a girl(10 years and 11 months), who had significantly acanthosis nigricans and body subcutaneous fat loss. The examination of the girl showed hyperinsulinemia, impaired glucose tolerance, advanced bone age, low adiponectin and polycystic ovary. The compound heterozygous mutations were identified, which was c.646A>T:p.K216*(PVS1_Strong+ PM2+PM3 ( inherited from her father) and c.406G>A:p.G136R(PM3_Strong+PM1+PM2+PP3 (inherited from her mother) in AGPAT2 gene. The mutation of two gene loci could be pathogenic, which had not been reported in CNKI database. All 5 Chinese cases in CNKI database were reported before (including 2 males and 3 females, and age was between 66 days and 26 years old) showed the absence of adipose tissue, in which two patients presented severe acanthosis nigricans. Conclusions: The CGL1 is rare in Chinese population, and it should be considered as the patients present the acanthosis nigricans and absence of adipose tissue, and its diagnosis depends gene detection.
SONG Zongxian, DONG Zhiya, LU Ziwen, LI Yanxiao, CHEN Ye . Genotype and clinical phenotype in congenital generalized lipodystrophy type 1: analysis and literature review[J]. Journal of Diagnostics Concepts & Practice, 2022 , 21(05) : 592 -597 . DOI: 10.16150/j.1671-2870.2022.05.008
[1] | Agarwal AK, Simha V, Oral EA, et al. Phenotypic and genetic heterogeneity in congenital generalized lipodystrophy[J]. J Clin Endocrinol Metab, 2003, 88(10):4840-4847. |
[2] | Akinci B, Onay H, Demir T, et al. Natural History of Congenital Generalized Lipodystrophy: A Nationwide Study From Turkey[J]. J Clin Endocrinol Metab, 2016, 101(7):2759-2767. |
[3] | Magré J, Delépine M, Van Maldergem L, et al. Prevalence of mutations in AGPAT2 among human lipodystrophies[J]. Diabetes, 2003, 52(6):1573-1578. |
[4] | 郭丹丹, 刘小凤, 段元冬. 66日龄婴儿发现多发皮下结节1月余[J]. 中国当代儿科杂志, 2020, 22(8):903-908. |
[4] | Guo DD, Liu XF, Duan YD. Multiple subcutaneous no-dules for 46 days in an infant aged 66 days[J]. Chin J Contemp Pediatr, 2020, 22(8):903-908. |
[5] | Agarwal AK, Arioglu E, de Almeida S, et al. AGPAT2 is mutated in congenital generalized lipodystrophy linked to chromosome 9q34[J]. Nat Genet, 2002, 31(1):21-23. |
[6] | Liu Y, Li D, Ding Y, et al. Further delineation of AGPAT2 and BSCL2 related congenital generalized lipodystrophy in young infants[J]. Eur J Med Genet, 2019, 62(9):103542. |
[7] | 王怡萍, 朱彦丽, 白晋丽, 等. AGPAT2基因新变异导致先天性全身性脂肪代谢障碍Ⅰ型一例[J]. 中华医学遗传学杂志, 2020, 37(10):1158-1161. |
[7] | Wang YP, Zhu YL, Bai JL, et al. Identification of a novel AGPAT2 variant in a Chinese patient with congenital generalized lipodystrophy type 1[J]. Chin J Med Genet, 2020, 37(10):1158-1161. |
[8] | 孟源源, 吴蔚, 黄轲, 等. AGPAT2基因变异致先天性全身脂肪营养不良症1例报告并文献复习[J]. 临床儿科杂志, 2020, 38(8):599-602. |
[8] | Meng YY, Wu W, Huang K, et al. Congenital generalized lipodystrophy caused by mutation of AGPAT2 gene: a case report and literature review[J]. J Chin Pediatr, 2020, 38(8):599-602. |
[9] | 张娟, 章钟允, 李浩榕, 等. AGPAT2基因复合杂合突变导致全身性脂肪营养不良1型一例并文献复习[J]. 中华内分泌代谢杂志, 2021, 37(9):840-844. |
[9] | Zhang J, Zhang ZY, Li HR, et al. Generalized lipodystrophy type 1 due to compound heterozygous mutation of AGPAT2 gene: One case report and literature teview[J]. Chin J Endocrinol Metab, 2021, 37(9):840-844. |
[10] | Patni N, Garg A. Congenital generalized lipodystrophies--new insights into metabolic dysfunction[J]. Nat Rev Endocrinol, 2015, 11(9):522-534. |
[11] | Lima JG, Nobrega LH, de Lima NN, et al. linical and laboratory data of a large series of patients with congenital generalized lipodystrophy[J]. Diabetol Metab Syndr, 2016, 8:23. |
[12] | Garg A. Acquired and inherited lipodystrophies[J]. N Engl J Med, 2004, 350(12):1220-1234. |
[13] | Garg A. Lipodystrophies[J]. Am J Med, 2000, 108(2):143-152. |
[14] | Ren M, Shi J, Jia J, et al. Genotype-phenotype correlations of Berardinelli-Seip congenital lipodystrophy and novel candidate genes prediction[J]. OOrphanet J Rare Dis, 2020, 15(1):108. |
[15] | Subauste AR, Das AK, Li X, et al. Alterations in lipid signaling underlie lipodystrophy secondary to AGPAT2 mutations[J]. Diabetes, 2012, 61(11):2922-2931. |
[16] | Vettor R, Milan G, Rossato M, et al. Review article: adipocytokines and insulin resistance[J]. Aliment Pharmacol Ther, 2005, 22(Suppl 2):3-10. |
[17] | Antuna-Puente B, Boutet E, Vigouroux C, et al. Higher adiponectin levels in patients with Berardinelli-Seip congenital lipodystrophy due to seipin as compared with 1-acylglycerol-3-phosphate-o-acyltransferase-2 deficiency[J]. J Clin Endocrinol Metab, 2010, 95(3):1463-1468. |
[18] | Musso C, Cochran E, Javor E, et al. The long-term effect of recombinant methionyl human leptin therapy on hyperandrogenism and menstrual function in female and pituitary function in male and female hypoleptinemic lipodystrophic patients[J]. Metabolism, 2005, 54(2):255-263. |
[19] | Araújo-Vilar D, Santini F. Diagnosis and treatment of lipodystrophy: a step-by-step approach[J]. J Endocrinol Invest, 2019, 42(1):61-73. |
/
〈 |
|
〉 |